How soon will you see results from Wegovy?

You've done your first injection. What's actually happening right now?

The first pen feels like a milestone, but the biological changes are quieter than most people expect. Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist, it works by mimicking a gut hormone that signals fullness to the brain and slows the rate at which your stomach empties. At the starter dose (0.25 mg), the medicine is primarily settling into your system. Appetite suppression at this level is mild for most people. The dose exists to let your body adjust, not to drive rapid weight change from the outset.

What you might actually notice first isn't a lower number on the scales, it's smaller portions feeling satisfying, or losing interest in snacking mid-afternoon. Some people find the urge to eat past fullness just fades. That shift in appetite is often the earliest meaningful signal that the medicine is working, and if you're wondering how soon you can expect to see results from Wegovy, that page breaks down what the evidence says at each stage of treatment. According to the NHS semaglutide medicines page, common side effects in these early weeks are gastrointestinal (nausea, indigestion, changes in bowel habit) and tend to be at their most noticeable after starting or after a dose increase.

If week one feels unremarkable, that's not a sign something has gone wrong. The titration schedule is doing its job.

Weeks four to twelve: when most people start seeing the results they were hoping for

This is usually when the scales start to move in a way that feels real. By the time you reach the 1 mg dose (typically around week eight under the standard titration) appetite suppression is more pronounced and the calorie reduction it produces starts to accumulate into visible weight loss. The STEP 1 trial published in the New England Journal of Medicine followed adults over 68 weeks; by around the three-month mark, participants on semaglutide had lost meaningfully more than those on placebo, with average total loss reaching around 15% of starting body weight by the end of the trial.

Real-world results vary. Weight loss in the first three months can range from a couple of kilograms to noticeably more, depending on dose, diet, activity, and individual metabolism. If you want a fuller picture of the results people typically see with Wegovy, including what the evidence shows at different dose levels, that page covers the clinical data in detail.

One practical note on timing: if you're tracking progress weekly, try to weigh yourself on the same day and time each week. A measurement on a Monday after a weekend away will look different from one on a Friday morning, even if the trend is the same. That kind of noise in the data is normal and worth knowing about before you start reading too much into a single weigh-in.

What affects how quickly you see results?

Several factors genuinely shape the pace. Dose is the biggest lever, you're on a titration schedule, so the highest doses (1.7 mg and 2.4 mg) do more work than the earlier ones. Most people aren't on maintenance dose until around week 16 to 20. The full timeline for Wegovy to work is longer than many people realise at the start, and that's worth framing clearly.

Beyond dose, what you eat alongside the injections matters. Wegovy is licensed for use alongside a reduced-calorie diet and increased activity, it reduces appetite, but food choices still affect the rate of progress. People who pair the medicine with meaningful dietary changes tend to see faster early results than those relying on appetite suppression alone. Sleep, stress and any underlying metabolic conditions all play a role too, which is why the prescriber's assessment covers more than just your BMI.

If you're considering the cost of ongoing treatment as part of your planning, the Wegovy cost context page explains what a legitimate private prescription includes and how pricing is structured. It's worth reading before comparing providers.

Finally, it's worth knowing that the 7.2 mg dose (approved by the MHRA in January 2026 and available as a dedicated single-dose pen from April 2026) produced around 20.7% average weight loss over 72 weeks in trials. That's a higher ceiling than the 2.4 mg maintenance dose, and its availability through a private clinical consultation is worth raising with your prescriber if you're already at the 2.4 mg level.

When to flag slow progress to your prescriber

If you've been on your maintenance dose for six months and have lost less than 5% of your starting body weight, that's the clinical marker at which NICE guidance suggests reconsidering whether treatment is working for you. This isn't a reason to panic after a slow month, it's a longer-term review point. Your prescriber is the right person to assess it in context, looking at what else has changed and whether there are reasons the response has been limited.

For people tracking their progress in the earlier months, the pattern to look for is a gradual trend downward over eight to twelve weeks, not a steep drop in the first fortnight. If your progress feels stalled and you're unsure whether that's normal, that's exactly the kind of question that belongs with a clinician. At nume, prescribers are available for aftercare seven days a week, questions like this don't have to wait for a scheduled appointment. You can also browse frequently asked questions or contact the team directly if something feels unclear. When you're ready to talk through eligibility and what treatment might look like for you, checking your eligibility is the place to start.